{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:09:42Z","timestamp":1786482582156,"version":"build-2736575974"},"reference-count":6,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Rare Tumors"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:p>Multiple myeloma is the second most common plasma cell malignancy, characterized by uncontrolled proliferation of plasma cells within the bone marrow. ELREXFIO\u2122 (elranatamab-bcmm) is a recently FDA-approved drug for relapsed and refractory multiple myeloma. The progression of multiple myeloma involves interactions with various bone marrow cell types, and targeting this microenvironment has shown promising results in inhibiting its growth and osteolysis. ELREXFIO, a bispecific antibody targeting CD3 and BCMA, activates cytotoxic T-lymphocyte responses against BCMA-expressing myeloma cells. Clinical trials, such as MagnetisMM-3, demonstrated significant response rates and long-term tolerability. Its approval offers hope to multiple myeloma patients, especially those with relapsed or refractory cases, as innovative therapies like ELREXFIO continue to improve outcomes in this challenging malignancy.<\/jats:p>","DOI":"10.1177\/20363613231207483","type":"journal-article","created":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T01:44:23Z","timestamp":1697075063000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Elrexfio\u2122 (elranatamab-bcmm): The game-changer in treatment of multiple myeloma"],"prefix":"10.1177","volume":"15","author":[{"given":"Taruba","family":"Rais","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4871-4910","authenticated-orcid":false,"given":"Afsheen","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-0183","authenticated-orcid":false,"given":"Rumaisa","family":"Riaz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"bibr1-20363613231207483","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.2.1"},{"key":"bibr2-20363613231207483","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.019"},{"key":"bibr3-20363613231207483","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"bibr4-20363613231207483","volume-title":"FDA grants accelerated approval to elranatamab-bcmm for multiple","author":"Center for Drug Evaluation and Research"},{"key":"bibr5-20363613231207483","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13038"},{"key":"bibr6-20363613231207483","volume-title":"Elranatamab"}],"container-title":["Rare Tumors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20363613231207483","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20363613231207483","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20363613231207483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:11:31Z","timestamp":1777590691000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20363613231207483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":6,"alternative-id":["10.1177\/20363613231207483"],"URL":"https:\/\/doi.org\/10.1177\/20363613231207483","relation":{},"ISSN":["2036-3613","2036-3613"],"issn-type":[{"value":"2036-3613","type":"print"},{"value":"2036-3613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]},"article-number":"20363613231207483"}}